Success Item Removed From Cart

Basket Summary
Close

Your Cart is Empty

Subtotal
$0
Sales Tax
$0
Total
$0
Back to browsing

Insomnia Pipeline Drugs Market Report Overview

Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches, and distress in the stomach and intestines. Risk factors include age, mental health disorders, stress, and shift working.

The Insomnia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects.

Insomnia Pipeline Drugs Market Segmentation by Targets

Some of the targets of the Insomnia pipeline drugs market are Orexin Receptor Type 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Orexin Receptor Type 1, Melatonin Receptor Type 1A, Melatonin Receptor Type 1B, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1, and Gamma-Aminobutyric Acid Type A Receptor Subunit.

Insomnia Pipeline Drugs Market Analysis, by Targets

Insomnia Pipeline Drugs Market Analysis, by Targets

For more Insomnia pipeline drugs market target insights, download a free report sample

Insomnia Pipeline Drugs Market Segmentation by Mechanism of Actions

Some of the mechanisms of action of the Insomnia pipeline drugs market are Orexin Receptor Type 2 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Orexin Receptor Type 1 Antagonist, Melatonin Receptor Type 1A Agonist, Melatonin Receptor Type 1B Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit Agonist.

Insomnia Pipeline Drugs Market Analysis, by Mechanism of Actions

Insomnia Pipeline Drugs Market Analysis, by Mechanism of Actions

For more mechanism of action insights into the Insomnia pipeline drugs market, download a free report sample

Insomnia Pipeline Drugs Market Segmentation by Routes of Administration

The key routes of administration in the Insomnia pipeline drugs market are oral, sublingual, intravenous, nasal, transdermal, buccal, inhalational, and parenteral.

Insomnia Pipeline Drugs Market Analysis, by Routes of Administration

Insomnia Pipeline Drugs Market Analysis, by Routes of Administration

For more routes of administration insights into the Insomnia pipeline drugs market, download a free report sample

Insomnia Pipeline Drugs Market Segmentation by Molecule Types

The molecule types in the Insomnia pipeline drugs market are Small Molecule and Biologic.

Insomnia Pipeline Drugs Market Analysis, by Molecule Types

Insomnia Pipeline Drugs Market Analysis, by Molecule Types

For more molecule type insights into the Insomnia pipeline drugs market, download a free report sample

Competitive Landscape

Some of the key companies in the Insomnia pipeline drugs market are Idorsia Pharmaceutical Ltd, Taisho Pharmaceutical Holdings Co Ltd, Zelira Therapeutics Ltd, Evotec SE, Imbrium Therapeutics LP, Johnson & Johnson, and Acahealth Pharma and Biotech Co Ltd.

Insomnia Pipeline Drugs Market Analysis, by Companies

Insomnia Pipeline Drugs Market Analysis, by Companies

To know more about the Insomnia pipeline drugs market companies, download a free report sample

Insomnia Pipeline Drugs Market Report Overview

Key Targets Orexin Receptor Type 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Orexin Receptor Type 1, Melatonin Receptor Type 1A, Melatonin Receptor Type 1B, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1, and Gamma-Aminobutyric Acid Type A Receptor Subunit
Key Mechanism of Actions Orexin Receptor Type 2 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Orexin Receptor Type 1 Antagonist, Melatonin Receptor Type 1A Agonist, Melatonin Receptor Type 1B Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit Agonist
Key Routes of Administration Oral, Sublingual, Intravenous, Nasal, Transdermal, Buccal, Inhalational, and Parenteral
Key Molecule Types Small Molecule and Biologic
Key Companies Idorsia Pharmaceutical Ltd, Taisho Pharmaceutical Holdings Co Ltd, Zelira Therapeutics Ltd, Evotec SE, Imbrium Therapeutics LP, Johnson & Johnson, and Acahealth Pharma and Biotech Co Ltd

Scope

This report provides:

  • A snapshot of the global therapeutic landscape of Insomnia.
  • Reviews of pipeline therapeutics for Insomnia by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • Reviews key companies involved in Insomnia therapeutics and enlists all their major and minor projects.
  • Evaluation of Insomnia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • All the dormant and discontinued pipeline projects.
  • Reviews of the latest news related to pipeline therapeutics for Insomnia.

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Insomnia.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

FAQs

  • Some of the key targets of the Insomnia pipeline drugs market are the Orexin Receptor Type 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Orexin Receptor Type 1, Melatonin Receptor Type 1A, Melatonin Receptor Type 1B, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1, and Gamma-Aminobutyric Acid Type A Receptor Subunit.

  • Some of the key mechanisms of action in the Insomnia pipeline drugs market are Orexin Receptor Type 2 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Orexin Receptor Type 1 Antagonist, Melatonin Receptor Type 1A Agonist, Melatonin Receptor Type 1B Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit Agonist.

  • The key routes of administration in the Insomnia pipeline drugs market are oral, sublingual, intravenous, nasal, transdermal, buccal, inhalational, and parenteral.

  • The molecule types in the Insomnia pipeline drugs market are Small Molecule and Biologic.

  • Some of the key companies in the Insomnia pipeline drugs market are Idorsia Pharmaceutical Ltd, Taisho Pharmaceutical Holdings Co Ltd, Zelira Therapeutics Ltd, Evotec SE, Imbrium Therapeutics LP, Johnson & Johnson, and Acahealth Pharma and Biotech Co Ltd.

What our clients have to say

More Reports

View More Reports